Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)
ANNOUNCEMENT
PRINCIPAL FINANCIAL DATA OF SINOPHARM (CNCM LTD)
FOR THE THREE MONTHS ENDED 31 MARCH 2021
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).
Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the "Company") dated 23 April 2021 (the "Announcement") in relation to the first quarterly report for the three months ended
31 March 2021 (the "Reporting Period") of China National Medicines Corporation Ltd. ("SINOPHARM (CNCM LTD)"), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange
(stock code: 600511).
The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of SINOPHARM (CNCM LTD) for the three months ended 31 March 2021 as set out in the Announcement.
1
PRINCIPAL FINANCIAL DATA OF SINOPHARM (CNCM LTD)
As at the end of this | |
Reporting Period | |
Total assets | 24,667,366,766.59 |
Net assets attributable to | |
shareholder of listed | 11,736,297,903.42 |
company |
From the beginning of the year to the end of the Reporting Period
Unit: Yuan | |
Currency: RMB | |
Increase/decrease at | |
the end of this | |
Last year-end | Reporting Period as |
compared with last | |
year-end (%) | |
24,904,932,990.82 | -0.95 |
11,443,638,059.13 | 2.56 |
From the beginning of | Increase/decrease as |
last year to the end of | compared with the |
the reporting period of | same period of last |
the last year | year (%) |
Net cash flow arising from operating activities
Revenue
Net profit attributable to shareholders of the listed company
Net profit attributable to shareholders of the listed company after deducting non- recurring gains and losses
-1,202,178,079.00
From the beginning of the year to the end of the Reporting Period
10,346,847,263.05
297,809,564.48
291,764,304.58
-1,147,897,586.80 | N/A |
From the beginning of | Increase/decrease as |
last year to the end of | compared with the |
the reporting period of | same period of last |
the last year | year (%) |
8,209,804,658.59 | 26.03 |
231,972,537.64 | 28.38 |
193,681,077.30 | 50.64 |
Weighted average | 2.57% |
return on net assets (%) | |
Basic earnings per | 0.3947 |
share (Yuan/Share) | |
Diluted earnings per | 0.3947 |
share (Yuan/Share) | |
2.18% | increased by 0.39 |
percentage point | |
0.3075 | 28.36 |
0.3075 | 28.36 |
2
By order of the Board
Sinopharm Group Co. Ltd.
Yu Qingming
Chairman
Shanghai, the PRC
23 April 2021
As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.
-
The Company is registered as a non-Hong Kong company under the Hong Kong Companies
Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".
3
Attachments
- Original document
- Permalink
Disclaimer
Sinopharm Group Co. Ltd. published this content on 23 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 April 2021 11:07:00 UTC.